Abemaciclib + SRS for Breast Cancer Brain Metastases
Trial Summary
Abemaciclib is unique because it is a CDK4/6 inhibitor that, when combined with endocrine therapy, has shown effectiveness in treating hormone receptor-positive breast cancer with brain metastases, a condition that typically has a poor prognosis and limited treatment options. This combination has demonstrated the ability to achieve partial remission in brain metastases, offering a novel approach compared to traditional therapies.
25678Abemaciclib, when used in combination with endocrine therapy for breast cancer, has shown a tolerable safety profile in clinical trials. Common side effects include diarrhea, infections, and neutropenia (low white blood cell count), but these are generally manageable.
23468Research shows that Abemaciclib, when combined with endocrine therapy, significantly improves progression-free survival in patients with advanced hormone receptor-positive, HER2-negative breast cancer. This suggests it may be effective in managing breast cancer brain metastases as well.
12368The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
Eligibility Criteria
This trial is for individuals with HR+/HER2- metastatic breast cancer brain metastases. Participants can have had prior radiation treatments if there's measurable disease not previously treated with radiation. They must be able to undergo stereotactic radiosurgery, have ≤ 15 brain lesions eligible for this treatment, and a performance status of 0 to 2. Women must test negative for pregnancy and agree to use contraception.Inclusion Criteria
Exclusion Criteria
Participant Groups
- Hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer
- HR+, HER2- node-positive early breast cancer
- HR+, HER2- advanced or metastatic breast cancer
- HR+, HER2- node-positive early breast cancer